MICROBIOLOGICAL FEATURES OF THE COURSE OF WIDESPREAD DRUG-RESISTANT PULMONARY TUBERCULOSIS
Keywords:
microbiological features, drug resistance, pulmonary tuberculosisAbstract
The massiveness of bacterial excretion in pulmonary tuberculosis is an indirect indicator reflecting the cavity character of changes in lung tissue and the density of the bacterial population. A prospective examination of 135 patients with extensively drug-resistant (XDR) pulmonary tuberculosis was conducted. The study included 68 men (45.8%) and 147 women (67%) aged 18 to 65 years. The bacteriological characteristics of XDR-TB of the lungs in the group of previously treated patients were significantly more pronounced in most parameters.
References
Abdullaev, R.Yu. Hepatotoxic reactions in the treatment of newly diagnosed patients with pulmonary tuberculosis with multidrug–resistant pathogen / R. Yu. Abdullaev, O. G. Komissarova, E. S. Chumakova [et al.] // Tuberculosis and lung diseases. – 2019. – Vol. 97. – No. 7. - pp. 21-27. (In Russian)
Baranova, O.N. Pulmonary tuberculosis with multidrug–resistant pathogen // Notes of a scientist. – 2015. - No. 6-1. – pp. 19-21. (In Russian)
Kuzmina, N.V. The course and effectiveness of treatment of tuberculosis with multiple and broad drug resistance // Fundamental and applied problems of human health in the North: A collection of materials of the V All-Russian Scientific and practical conference, Surgut, October 27, 2020. Surgut: Surgut State University, 2020. pp. 82-88. (In Russian)
Kranzer, K. New WHO Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared? // Am J Respir Crit Care Med. - 2019. - Apr 26. [Epub ahead of print].
Vjecha, M.J. Accelerating the development of therapeutic strategies for drug‐resistant tuberculosis // Nat Rev Drug Discov. - 2018.-Vol.17(9). - P.607–608.
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, World Health Organization, 2020.
Zhao, Y. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study // Clin Infect Dis 2018.
